Localized cutaneous fibrosing disorders

Rheumatic Disease Clinics of North America

Volumn 39, Issue 2, 2013, Pages 347-364

  Yaqub, Aaliya ^a   Chung, Lorinda ^a   Rieger, Kerri E ^a   Fiorentino, David F ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic graft versus host disease; Cutaneous fibrosis; Localized scleroderma; Morphea; Nephrogenic systemic fibrosis; Scleredema; Scleromyxedema

Indexed keywords

5 HYDROXYTRYPTOPHAN; ANTIMALARIAL AGENT; BALICATIB; BISOPROLOL; BLEOMYCIN; BOSENTAN; BROMOCRIPTINE; CALCINEURIN; CALCIPOTRIOL; CARBIDOPA; CD34 ANTIGEN; COLLAGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMATINIB; IMMUNOLOGIC AGENT; INFLIXIMAB; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; PENICILLIN DERIVATIVE; PENTAZOCINE; PENTOXIFYLLINE; PEPLEOMYCIN; PIMECROLIMUS; TACROLIMUS; TAMOXIFEN; UNINDEXED DRUG;

BORRELIA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; EOSINOPHILIC FASCIITIS; HISTOPATHOLOGY; HUMAN; INCIDENCE; MALIGNANT NEOPLASTIC DISEASE; MORPHEA; NEPHROGENIC SYSTEMIC FIBROSIS; OCCUPATIONAL EXPOSURE; OSTEOPOROSIS; PLASMAPHERESIS; PREVALENCE; PRIORITY JOURNAL; PUVA; RADIATION INJURY; REVIEW; SCLEREDEMA; SCLEROMYXEDEMA; SEPSIS; SKIN FIBROSIS; SYSTEMIC SCLEROSIS;

CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; EOSINOPHILIA; FASCIITIS; GRAFT VS HOST DISEASE; HUMANS; INTERDISCIPLINARY COMMUNICATION; NEPHROGENIC FIBROSING DERMOPATHY; SCLEREDEMA ADULTORUM; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; SCLEROMYXEDEMA; SKIN DISEASES;

EID: 84876703353     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2013.02.013     Document Type: Review

References (61)

1. Dehen L., Roujeau J.C., Cosnes A., et al. Internal involvement in localized scleroderma. Medicine 1994, 73(5):241-245.
2. Zulian F., Vallongo C., Woo P., et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum 2005, 52(9):2873-2881.
3. Fett N., Werth V.P. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 2011, 64(2):217-228. [quiz: 229-30].
4. Peterson L.S., Nelson A.M., Su W.P., et al. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. J Rheumatol 1997, 24(1):73-80.
5. Murray K.J., Laxer R.M. Scleroderma in children and adolescents. Rheum Dis Clin North Am 2002, 28(3):603-624.
6. Zulian F., Athreya B.H., Laxer R., et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford) 2006, 45(5):614-620.
7. Christen-Zaech S., Hakim M.D., Afsar F.S., et al. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol 2008, 59(3):385-396.
8. Leitenberger J.J., Cayce R.L., Haley R.W., et al. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol 2009, 145(5):545-550.
9. Peterson L.S., Nelson A.M., Su W.P. Classification of morphea (localized scleroderma). Mayo Clin Proc 1995, 70(11):1068-1076.
10. Laxer R.M., Zulian F. Localized scleroderma. Curr Opin Rheumatol 2006, 18(6):606-613.
11. Kreuter A., Krieg T., Worm M., et al. AWMF Guideline no. 013/066. Diagnosis and therapy of circumscribed scleroderma. J Dtsch Dermatol Ges 2009, 7(Suppl 6):S1-S14. [in German].
12. Kreuter A. Localized scleroderma. Dermatol Ther 2012, 25(2):135-147.
13. Buechner S.A., Rufli T. Atrophoderma of Pasini and Pierini. Clinical and histopathologic findings and antibodies to Borrelia burgdorferi in thirty-four patients. J Am Acad Dermatol 1994, 30(3):441-446.
14. Saleh Z., Abbas O., Dahdah M.J., et al. Atrophoderma of Pasini and Pierini: a clinical and histopathological study. J Cutan Pathol 2008, 35(12):1108-1114.
15. Murphy P.K., Hymes S.R., Fenske N.A. Concomitant unilateral idiopathic atrophoderma of Pasini and Pierini (IAPP) and morphea. Observations supporting IAPP as a variant of morphea. Int J Dermatol 1990, 29(4):281-283.
16. Jacobson L., Palazij R., Jaworsky C. Superficial morphea. J Am Acad Dermatol 2003, 49(2):323-325.
17. Jablonska S., Blaszczyk M. Is superficial morphea synonymous with atrophoderma Pasini-Pierini?. J Am Acad Dermatol 2004, 50(6):979-980. [author reply: 980].
18. Tekin N.S., Altinyazar H.C., Tekin I.O., et al. Disabling pansclerotic morphoea: a case report. Int J Clin Pract 2010, 64(1):99-101.
19. Lebeaux D., Sene D. Eosinophilic fasciitis (Shulman disease). Best Pract Res Clin Rheumatol 2012, 26(4):449-458.
20. Orozco-Covarrubias L., Guzman-Meza A., Ridaura-Sanz C., et al. Scleroderma 'en coup de sabre' and progressive facial hemiatrophy. Is it possible to differentiate them?. J Eur Acad Dermatol Venereol 2002, 16(4):361-366.
21. Blaszczyk M., Krolicki L., Krasu M., et al. Progressive facial hemiatrophy: central nervous system involvement and relationship with scleroderma en coup de sabre. J Rheumatol 2003, 30(9):1997-2004.
22. Torrelo A., Suarez J., Colmenero I., et al. Deep morphea after vaccination in two young children. Pediatr Dermatol 2006, 23(5):484-487.
23. Ho J., Rothchild Y.H., Sengelmann R. Vitamin B12-associated localized scleroderma and its treatment. Dermatol Surg 2004, 30(9):1252-1255.
24. Peroni A., Zini A., Braga V., et al. Drug-induced morphea: report of a case induced by balicatib and review of the literature. J Am Acad Dermatol 2008, 59(1):125-129.
25. Haustein U.F., Haupt B. Drug-induced scleroderma and sclerodermiform conditions. Clin Dermatol 1998, 16(3):353-366.
26. Asano Y., Ihn H., Shikada J., et al. A case of peplomycin-induced scleroderma. Br J Dermatol 2004, 150(6):1213-1214.
27. Kvernmo T., Hartter S., Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006, 28(8):1065-1078.
28. Liddle B.J. Development of morphoea in rheumatoid arthritis treated with penicillamine. Ann Rheum Dis 1989, 48(11):963-964.
29. Runger T.M., Adami S., Benhamou C.L., et al. Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib. J Am Acad Dermatol 2012, 66(3):e89-e96.
30. Sozeri B., Gulez N., Aksu G., et al. Pesticide-induced scleroderma and early intensive immunosuppressive treatment. Arch Environ Occup Health 2012, 67(1):43-47.
31. Bovenzi M., Barbone F., Pisa F.E., et al. A case-control study of occupational exposures and systemic sclerosis. Int Arch Occup Environ Health 2004, 77(1):10-16.
32. Nietert P.J., Sutherland S.E., Silver R.M., et al. Is occupational organic solvent exposure a risk factor for scleroderma?. Arthritis Rheum 1998, 41(6):1111-1118.
33. Stinco G., Piccirillo F., de Francesco V., et al. Scleroderma-like lesions and Parkinson's disease: possible links with exposure to pesticides. Eur J Dermatol 2007, 17(3):256-257.
34. Herrmann T., Gunther C., Csere P. Localized morphea-a rare but significant secondary complication following breast cancer radiotherapy. Case report and review of the literature on radiation reaction among patients with scleroderma/morphea. Strahlenther Onkol 2009, 185(9):603-607.
35. Davis D.A., Cohen P.R., McNeese M.D., et al. Localized scleroderma in breast cancer patients treated with supervoltage external beam radiation: radiation port scleroderma. J Am Acad Dermatol 1996, 35(6):923-927.
36. Bleasel N.R., Stapleton K.M., Commens C., et al. Radiation-induced localized scleroderma in breast cancer patients. Australas J Dermatol 1999, 40(2):99-102.
37. Schaffer J.V., Carroll C., Dvoretsky I., et al. Postirradiation morphea of the breast presentation of two cases and review of the literature. Dermatology 2000, 200(1):67-71.
38. Cheah N.L., Wong D.W., Chetiyawardana A.D. Radiation-induced morphea of the breast: a case report. J Med Case Rep 2008, 2:136.
39. Laetsch B., Hofer T., Lombriser N., et al. Irradiation-induced morphea: x-rays as triggers of autoimmunity. Dermatology 2011, 223(1):9-12.
40. Zwischenberger B.A., Jacobe H.T. A systematic review of morphea treatments and therapeutic algorithm. J Am Acad Dermatol 2011, 65(5):925-941.
41. Martini G., Ramanan A.V., Falcini F., et al. Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil. Rheumatology 2009, 48(11):1410-1413.
42. Meguerditchian C., Jacquet P., Beliard S., et al. Scleredema adultorum of Buschke: an under recognized skin complication of diabetes. Diabetes Metab 2006, 32(5 Pt 1):481-484.
43. Beers W.H., Ince A., Moore T.L. Scleredema adultorum of Buschke: a case report and review of the literature. Semin Arthritis Rheum 2006, 35(6):355-359.
44. Dziadzio M., Anastassiades C.P., Hawkins P.N., et al. From scleredema to AL amyloidosis: disease progression or coincidence? Review of the literature. Clin Rheumatol 2006, 25(1):3-15.
45. Nashel J., Steen V. Scleroderma mimics. Curr Rheumatol Rep 2012, 14(1):39-46.
46. Konemann S., Hesselmann S., Bolling T., et al. Radiotherapy of benign diseases-scleredema adultorum Buschke. Strahlenther Onkol 2004, 180(12):811-814.
47. Alsaeedi S.H., Lee P. Treatment of scleredema diabeticorum with tamoxifen. J Rheumatol 2010, 37(12):2636-2637.
48. Jackson E.M., English J.C. Diffuse cutaneous mucinoses. Dermatol Clin 2002, 20(3):493-501.
49. Fleming K.E., Virmani D., Sutton E., et al. Scleromyxedema and the dermato-neuro syndrome: case report and review of the literature. J Cutan Pathol 2012, 39(5):508-517.
50. Sroa N., Campbell S., Bechtel M. Intravenous immunoglobulin therapy for scleromyxedema: a case report and review of literature. J Drugs Dermatol 2010, 9(3):263-265.
51. Efthimiou P., Blanco M. Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature. Semin Arthritis Rheum 2008, 38(3):188-194.
52. Cowper S.E., Robin H.S., Steinberg S.M., et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000, 356(9234):1000-1001.
53. Bernstein E.J., Schmidt-Lauber C., Kay J. Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure. Best practice & research. Clinical rheumatology 2012, 26(4):489-503.
54. Girardi M., Kay J., Elston D.M., et al. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol 2011, 65(6):1095-1106.e7.
55. Kay J., High W.A. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 2008, 58(8):2543-2548.
56. Cuffy M.C., Singh M., Formica R., et al. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrol Dial Transplant 2011, 26(3):1099-1101.
57. Hymes S.R., Alousi A.M., Cowen E.W. Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease. J Am Acad Dermatol 2012, 66(4):515.e1-515.e18. [quiz: 533-4].
58. Hymes S.R., Alousi A.M., Cowen E.W. Graft-versus-host disease: part II. Management of cutaneous graft-versus-host disease. J Am Acad Dermatol 2012, 66(4):535.e1-535.e16. [quiz: 551-2].
59. Chen G.L., Arai S., Flowers M.E., et al. A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Blood 2011, 118(15):4070-4078.
60. Magro L., Mohty M., Catteau B., et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood 2009, 114(3):719-722.
61. Olivieri A., Locatelli F., Zecca M., et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 2009, 114(3):709-718.